The Beneficial Effect of the COVID-19 Vaccine Booster Dose among Healthcare Workers in an Infectious Diseases Center

Skrzat‐Klapaczyńska, Agata; Bieńkowski, Carlo; Kowalska, Justyna D.; Paciorek, Marcin; Puła, Joanna; Krogulec, Dominika; Stengiel, Jarosław; Perlejewski, Karol; Osuch, Sylwia; Radkowski, Marek; Horban, Andrzéj

doi:10.3390/vaccines10040552

Cited by 11 publications

(9 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of our analysis were aimed to complement those published earlier by Skrzat-Klapaczy ńska and colleagues [1] on elucidating the effect of BNT162b2 booster immunization on anti-SARS-CoV-2 antibodies. For this purpose, we measured both total and IgG anti-SARS-CoV-2 antibodies, showing that both classes of antibodies considerably increased (by 31 and 22-fold, respectively) 1 month after receiving the BNT162b2 vaccine booster.…”

Section: Discussionmentioning

confidence: 62%

“…In a recent article published in this journal, Skrzat-Klapaczy ńska and colleagues [1] showed that a booster dose of the mRNA-based BNT162b2 vaccine was effective at increasing the serum values of SARS-CoV-2 IgG antibodies measured with the MAGLUMI SARS-CoV-2 S-RBD IgG assay over the maximum measurable level according to the method used by the authors (i.e., >433 BAU/mL). To provide further insights on this important aspect in terms of limiting SARS-CoV-2 infection and lowering the risk of developing serious complications from coronavirus disease 2019 (COVID-19), we monitored both total and IgG anti-SARS-CoV-2 antibodies response after BNT162b2 vaccine booster immunization in a cohort of ostensibly healthy healthcare workers, with a specific focus on emphasizing the potential correlation between the post-booster variation of these two antibodies classes.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Correlation between Anti-SARS-CoV-2 Total Antibodies and Spike Trimeric IgG after BNT162b2 Booster Immunization

Salvagno¹,

Lippi²

2022

Vaccines

View full text Add to dashboard Cite

Objective: In this work we monitored both total and IgG anti-SARS-CoV-2 antibodies responses after BNT162b2 vaccine booster immunization in a cohort of ostensibly healthy healthcare workers. Methods: The study population consisted of 266 subjects (median age, 46 years and interquartile range (IQR), 35–52 years; 168 females) undergoing homologous 30-µg BNT162b2 booster administration. Serum samples were collected immediately before the booster dose and 1 month after. Results: The concentration of anti-SARS-CoV-2 RBD total antibodies and anti-SARS-CoV-2 spike trimeric IgG increased by 31 (IQR, 16–53) and 22 (IQR, 11–43) folds, respectively, after receiving the BNT162b2 vaccine booster. A highly significant Spearman′s correlation was found between the relative increase (i.e., ratio of post-booster and pre-booster serum values) of anti-SARS-CoV-2 RBD total antibodies and anti-SARS-CoV-2 spike trimeric IgG (r = 0.86; p < 0.001). Conclusion: These results suggest that monitoring of post-BNT162b2 booster immunization for purposes of identifying “low responders” could be conducted almost interchangeably with either total or IgG anti-SARS-CoV-2 antibodies.

show abstract

Section: Discussionmentioning

confidence: 62%

Section: Introductionmentioning

confidence: 99%

Correlation between Anti-SARS-CoV-2 Total Antibodies and Spike Trimeric IgG after BNT162b2 Booster Immunization

Salvagno¹,

Lippi²

2022

Vaccines

View full text Add to dashboard Cite

show abstract

“…In general, there is agreement that individuals who have received two doses of COVID-19 vaccines should receive additional doses periodically [18]. Such additional doses have been shown to be beneficial and safe [19][20][21][22]. Additional doses are also strongly recommended for adults with underlying health conditions living in long-term care and for those living in high-risk environments [23,24].…”

Section: Introductionmentioning

confidence: 99%

The public’s attitude to and acceptance of periodic doses of the COVID-19 vaccine: A survey from Jordan

et al. 2022

View full text Add to dashboard Cite

Aims This study surveyed people regarding their acceptance of periodic doses (i.e., annual boosters) of the COVID-19 vaccine. Moreover, factors that correlate with attitudes toward periodic COVID-19 vaccines were assessed and identified. Method The study employed a cross-sectional methodology. The study questionnaire was distributed using Google Forms. Data were collected during the last quarter of 2021, and 1,416 adults (18 years old and over) from Jordan responded. Acceptance of COVID-19 periodic vaccine doses was calculated as a percentage of the total number of study participants, and their attitudes were scored. A multiple regression model was used to determine the predictors of public attitudes toward the annual dose of COVID-19 vaccines. Results The acceptance rate for receiving periodic doses of the COVID-19 vaccine was low (19.3%). Additionally, 26% of participants were unsure about receiving additional doses of the vaccine. However, 54.7% had a negative attitude toward getting periodic doses. The mean score for attitudes toward periodic doses was 47.9 (range: 29–66). Among the identified factors leading to decisions not to receive periodic doses were side effects (49.1%), waiting for further clinical studies (38.8%), and perceived no risk of contracting COVID-19 (17.7%). Regression analysis showed that income, educational attainment, and following the news about COVID-19 were predictors of participants’ attitudes toward the periodic COVID-19 vaccine. Conclusion Acceptance of periodic doses of the COVID-19 vaccine in Jordan is low, and the public’s attitude is generally negative. Health programs and educational interventions are needed to promote vaccine acceptance and positive attitudes.

show abstract

“…Antibody titers declined more rapidly in subjects with mild/asymptomatic SARS-CoV-2 infection [ 15 , 16 , 17 , 18 , 19 ]. A decreased trend of humoral immunity is also evident in vaccinated individuals after the second vaccine dose [ 7 , 20 ]; however, scarce data exist analyzing humoral responses after the administration of a third dose of the vaccine [ 21 , 22 ], and even fewer data focus on the ability of this vaccine to generate mucosal humoral immune responses.…”

Section: Introductionmentioning

confidence: 99%

Systemic and Mucosal Humoral Immune Response Induced by Three Doses of the BNT162b2 SARS-CoV-2 mRNA Vaccines

et al. 2022

View full text Add to dashboard Cite

BNT162b2 (BioNTech/Pfizer) was the first SARS-CoV-2 mRNA vaccine approved by the European Medicines Agency. We monitored the long-term humoral responses of healthcare workers (HCWs) who received three vaccine doses. A total of 59 healthcare workers were studied: 47 were never SARS-CoV-2-infected (naïve-HCWs), and 12 (infected-HCWs) recovered from COVID-19 before the first vaccine. Serum and saliva were collected at baseline (before the first dose), just before the second dose, 1, 3, 6, and 9 months after the second dose, and 10 days after the third vaccine. SARS-CoV-2-specific IgG and IgA were evaluated in serum and saliva, respectively, and the presence of neutralizing antibodies (NAb) was analyzed in serum. SARS-CoV-2-specific IgG peaked one month after the second vaccine in naïve-HCWs but right before this timepoint in infected-HCWs. IgG titers significantly decreased during follow-up and at month 9 were still detectable in 50% of naïve-HCWs and 90% of infected-HCWs. NAb were significantly decreased 6 months after the second vaccine in naïve-HCWs and 9 months after this dose in infected-HCWs. Salivary SARS-CoV-2-specific IgA titers were significantly higher in infected-HCWs and were undetectable 9 months after the second vaccine in 43% of the naïve-HCWs alone. The third vaccine greatly increased humoral IgG and mucosal IgA in both groups. Two BNT162b2 doses induced strong systemic and humoral immune responses; to note, these responses weakened over time, although they are more prolonged in individuals who had recovered from COVID-19. The third vaccine dose quickly boosts systemic and mucosal humoral responses.

show abstract

The Beneficial Effect of the COVID-19 Vaccine Booster Dose among Healthcare Workers in an Infectious Diseases Center

Cited by 11 publications

References 26 publications

Correlation between Anti-SARS-CoV-2 Total Antibodies and Spike Trimeric IgG after BNT162b2 Booster Immunization

Correlation between Anti-SARS-CoV-2 Total Antibodies and Spike Trimeric IgG after BNT162b2 Booster Immunization

The public’s attitude to and acceptance of periodic doses of the COVID-19 vaccine: A survey from Jordan

Systemic and Mucosal Humoral Immune Response Induced by Three Doses of the BNT162b2 SARS-CoV-2 mRNA Vaccines

Contact Info

Product

Resources

About